CIPLA vs AUROPHARMA: Stock Comparison
Head-to-head financial and trading comparison between Cipla Limited (CIPLA) and Aurobindo Pharma Limited (AUROPHARMA) in the Pharmaceuticals & Healthcare sector.
CIPLA
NSE: CIPLAAUROPHARMA
NSE: AUROPHARMAKey Metrics Comparison Table
| Metric | CIPLA | AUROPHARMA | Edge / Winner |
|---|---|---|---|
| Current Market Price (CMP) | ₹1,344.00 | ₹1,676.80 | — |
| 1-Year Price Return | +9.31% | +24.26% | AUROPHARMA (14.95% higher) |
| 52-Week High | ₹1,477.00 | ₹1,734.00 | — |
| 52-Week Low | ₹1,211.10 | ₹1,339.80 | — |
| 30-Day Annualized Volatility | 15.13% | 23.34% | CIPLA (Steadier) |
| 30-Day Average Daily Volume | 912,248 | 831,523 | CIPLA (Higher Liquidity) |
| Statutory Cost to Trade ₹1 Lakh | ₹118.50 | ₹118.50 | Identical statutory tariff |
Frequently Asked Questions
Between CIPLA and AUROPHARMA, which stock gave better returns over the last year?
AUROPHARMA has outperformed CIPLA over the past 12 months with a gain of 24.26% compared to 9.31%.
Which stock is less volatile: CIPLA or AUROPHARMA?
CIPLA demonstrated lower price volatility (15.13% annualized) compared to AUROPHARMA (23.34%). Lower volatility generally indicates steadier price action during market downturns.
What is the statutory cost to buy ₹1,00,000 of CIPLA vs AUROPHARMA?
Statutory exchange and government charges (STT, NSE turnover fees, SEBI fee, Stamp duty, and GST) are identical for delivery purchases of equal rupee value across both stocks, totaling approximately ₹118.50 on discount brokers offering zero delivery brokerage (like Zerodha or Dhan).
Are CIPLA and AUROPHARMA direct sector competitors?
Yes, both companies operate within the Pharmaceuticals & Healthcare sector in India and are actively tracked as sector peers by institutional and retail market participants.